MedTrace Logo

Flicker App for Minimal Hepatic Encephalopathy

NCT04415294 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2022-01-11

No results posted yet for this study

Summary

There is a great unmet clinical need for improved screening for MHE in patients with cirrhosis. We will demonstrate that the Flicker-App can be used in clinic as well as at home by patients with cirrhosis to measure CFF, a proven screening test for MHE. We will optimize the protocol, software, and hardware of the Flicker-App to create a product appropriate for production and distribution to patients

Conditions

  • Hepatic Encephalopathy

Interventions

DIAGNOSTIC_TEST

Critical flicker frequency

Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of Washington

    lead OTHER

Principal Investigators

  • George N Ioannou, MD, MS · University of Washington

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2023-05-31
Completion
2023-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04415294 on ClinicalTrials.gov